| Theme | Recent advance in the treatment of IBD based on the pathogenesis | |
|---|---|---|
| Title | Emerging therapies for inflammatory bowel disease | |
| Publish Date | 2018/05 | |
| Author | Hiroki Kiyohara | Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine |
| Author | Shinta Mizuno | Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine |
| Author | Takanori Kanai | Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine |
| [ Summary ] | Approximately 20 years have passed since the introduction of the first biologic, infliximab. It has produced a great advance in the treatment of inflammatory bowel disease (IBD). Recently, a variety of biologic mechanisms, such as anti cytokine antibodies, leukocyte trafficking inhibitors and Janus Kinase inhibitors have been developed and applied to clinical use. The deciding factors as to whether we use biologics, and how we should use them and who should be treated with them are being considered. In this paper, we discuss emerging therapies for IBD and their current status. | |